Drug pipeline
Explore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Thymocyte selection-associated high mobility group box protein TOX is a nuclear DNA-binding transcription factor and chromatin regulator belonging to the high mobility group (HMG)-box superfamily. It plays a critical role in the development of various immune cells, including CD4+ T cells, natural killer (NK) cells, and innate lymphoid cells (ILCs). In the context of chronic antigen stimulation, such as in cancer or chronic viral infections, TOX acts as a master regulator of CD8+ T-cell exhaustion by driving transcriptional and epigenetic changes that upregulate inhibitory receptors like PD-1. Additionally, TOX is overexpressed in certain lymphocytic malignancies, such as T-cell acute lymphoblastic leukemia (T-ALL) and cutaneous T-cell lymphoma (CTCL), where it promotes genomic instability and tumor cell survival. Although there are currently no FDA-approved drugs targeting TOX, experimental small molecule inhibitors (such as KI-TOX-A3 and 92778-A3) are being developed to disrupt its DNA-binding or protein-protein interactions, offering a promising therapeutic strategy to reverse T-cell exhaustion and treat hematological malignancies.
Inhibition of TOX protein-protein interactions (such as with KU70/80 or KAT7) or DNA-binding activity at its HMG-box domain, leading to downregulation of TOX expression, suppression of PD-1 expression, and reversal of T-cell exhaustion.
3 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Thymocyte selection-associated high mobility group box protein TOX (TOX).